Log in to your Inderes Free account to see all free content on this page.
Create account

Genovis

20.65 SEK

-1.67 %

1,631 following

GENO

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

-1.67 %
+2.23 %
+16.67 %
-2.82 %
-0.24 %
-14.32 %
-63.26 %
-56.98 %
-24.57 %

Genovis delivers biotechnology tools and technology platforms to the life sciences and pharmaceutical industries. The company develops enzyme and inhibitor technologies that facilitate, or are integral parts of, a wide range of processes from basic research to pharmaceutical manufacturing and diagnostics. The company operates on a global scale, with customers primarily in North America, Europe and East Asia. Genovis was founded in 1999 and is headquartered in Kävlinge.

Read more
Market cap
1.36B SEK
Turnover
668.04K SEK
Revenue
EBIT %
P/E
Dividend yield-%
Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
18.5.
2026

General meeting '26

23.7.
2026

Interim report Q2'26

10.11.
2026

Interim report Q3'26

ShowingAll content types

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio
Create account
Forum discussions
Time for the AGM. The management remains the same, and the remuneration system is being refined, linking it specifically to the development phase (dividends are not the target). Authorization is requested for a share issue of 6.6 million shares (which would mean a 10% dilution as...
4/17/2026, 8:38 PM
by LeBaron
6
I see this as a much more positive step than the previous news, moving towards participating in drug manufacturing technology rather than selling enzymes for others to research. So, two different lines are being built: Research tools and Therapeutics licensing. This new move has ...
3/26/2026, 6:22 AM
by LeBaron
6
MFN – 24 Jul 25 Genovis Expands License Agreement to Access Proprietary Enzyme Tech... Genovis AB, a leading provider of innovative enzyme technologies, today announced an expansion of its license agreement with Thermo Fisher Scientific to gain access to proprietary enzyme technology...
7/24/2025, 6:32 AM
by sillinkutoja
6
Inderes Genovis and Single Cell Discoveries Enter Strategic Partnership for... Genovis AB, a leading provider of innovative enzyme technologies, today announces a strategic partnership with Single Cell Discoveries to broaden the application of the SEQURNA® Thermostable... Genovis...
3/19/2026, 7:47 AM
by Simba
5
A bit of a monologue here. Oh well, at least I won’t start arguing with myself. The annual report provides more detail on the reflections I shared above. I hope to get answers from the AGM to at least these: how much of the 2025 growth came from ADC? (core revenue +17%, currency-...
4/27/2026, 2:25 PM
by LeBaron
4
Good that business is good. It seems to me that Genovis is a premier enzyme supplier whose products have unique properties and thus pricing power. I’m holding this with a small weighting, waiting for better times.
3/25/2026, 1:36 PM
by Clark kent
3
Nordnet Nordnet Tee säästämisestä osakkeisiin & rahastoihin hauskempaa. Sijoittaminen osakkeisiin, rahastoihin ja ETF:iin ilman tarpeettomia kuluja. Tervetuloa Suomen tyytyväisimpien sijoittajien joukkoon! Avaa tili jo tänään! Genovis and Plasmidsaurus Introduce SEQguard™ Dino Preserve...
3/31/2026, 3:14 PM
by LeBaron
2
Read more on our forum
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.